Futibatinib
- Generic Name
- Futibatinib
- Brand Names
- Lytgobi 20 Mg Daily Dose, Lytgobi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N6O3
- CAS Number
- 1448169-71-8
- Unique Ingredient Identifier
- 4B93MGE4AL
- Background
Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in som...
- Indication
Futibatinib is indicated to treat adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. In Europe, it is indicated in patients whose disease has progressed after at least one prior line of systemic therapy.
...
- Associated Conditions
- Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Associated Therapies
- -
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
A Study of TAS-120 in Patients With Advanced Solid Tumors
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT02052778
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Virginia Mason Cancer Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.